Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center.
Department of Pharmacy, National Cerebral and Cardiovascular Center.
Circ J. 2019 Jun 25;83(7):1607-1611. doi: 10.1253/circj.CJ-19-0125. Epub 2019 Jun 5.
Little is known about palliative sedation in terminally ill heart failure (HF) patients.
We retrospectively reviewed terminally ill HF patients who received palliative sedation from September 2013 to August 2018. Among 95 terminally ill HF patients, 25 were prescribed dexmedetomidine and 12 were prescribed midazolam at the end of life. Richmond Agitation-Sedation Scale was significantly reduced (P<0.01), but blood pressure and heart rate were unaltered after treatment in both the dexmedetomidine and midazolam groups.
Prescription of dexmedetomidine and/or midazolam might be feasible in selected terminally ill HF patients.
关于终末期心力衰竭（HF）患者的姑息性镇静，目前知之甚少。
我们回顾性分析了 2013 年 9 月至 2018 年 8 月接受姑息性镇静治疗的终末期 HF 患者。在 95 例终末期 HF 患者中，25 例在生命末期接受右美托咪定治疗，12 例接受咪达唑仑治疗。右美托咪定和咪达唑仑组治疗后 Richmond 躁动-镇静量表评分均显著降低（P<0.01），但血压和心率无变化。
在选择的终末期 HF 患者中，右美托咪定和/或咪达唑仑的处方可能是可行的。
